Bevacizumab
Showing 1 - 25 of 3,098
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation Trial (Onvansertib, FOLFIRI, Bevacizumab)
Not yet recruiting
- Metastatic Colorectal Cancer
- +2 more
- Onvansertib
- +3 more
- (no location specified)
Oct 24, 2023
Colorectal Cancer Trial (HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV,
Not yet recruiting
- Colorectal Cancer
- HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab
- HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
- (no location specified)
Jul 13, 2023
Adebrelimab, Hepatocellular Carcinoma, Transformation Trial in Xiamen (TACE with adebrelimab and bevacizumab)
Not yet recruiting
- Adebrelimab
- +4 more
- TACE with adebrelimab and bevacizumab
-
Xiamen, Fujian, ChinaThe First Affiliated Hospital of Xiamen University
Jul 25, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)
Withdrawn
- Hepatocellular Carcinoma
- Candonilimab
- Bevacizumab
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
Jun 1, 2023
Hepatocellular Carcinoma Non-resectable Trial in Taoyuan City (Atezolizumab, Bevacizumab, Proton radiotherapy)
Recruiting
- Hepatocellular Carcinoma Non-resectable
- Atezolizumab
- +2 more
-
Taoyuan City, TaiwanChang Gung Memorial Hospital at Linkou
Nov 17, 2023
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Completed
- Platinum-Resistant Fallopian Tube Carcinoma
- +8 more
- Bevacizumab
- Irinotecan Sucrosofate
-
Chicago, IllinoisNorthwestern University
Dec 21, 2022
Carcinoma, Ovarian Epithelial Trial in San Fermo Della Battaglia, Padova (Olaparib, Bevacizumab)
Recruiting
- Carcinoma, Ovarian Epithelial
- Olaparib
- Bevacizumab
-
San Fermo Della Battaglia, Como, Italy
- +1 more
Nov 2, 2023
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable Trial in Seoul (Atezolizumab plus
Recruiting
- Hepatocellular Carcinoma
- +4 more
- Atezolizumab plus bevacizumab, combined EBRT to vascular invasion
- Atezolizumab plus bevacizumab
-
Seoul, Korea, Republic ofAsan Medical Center
Aug 7, 2023
Colorectal Cancer, Metastatic Colon Cancer Trial (Ompenaclid (RGX-202-01) + FOLFIRI + Bevacizumab, Placebo + FOLFIRI +
Not yet recruiting
- Colorectal Cancer
- Metastatic Colon Cancer
- Ompenaclid (RGX-202-01) + FOLFIRI + Bevacizumab
- Placebo + FOLFIRI + Bevacizumab
- (no location specified)
Aug 1, 2023
Hepatocellular Carcinoma Trial in Nanjing, Shanghai (QL1706, Bevacizumab, Oxaliplatin injection)
Not yet recruiting
- Hepatocellular Carcinoma
- QL1706
- +4 more
-
Nanjing, Jiangsu, China
- +1 more
Jul 28, 2023
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Recruiting
- Neurofibromatosis 2
- Bevacizumab Zirconium Zr-89
-
Leiden, Zuid-Holland, NetherlandsLeiden University Medical Center
Jan 5, 2023
Colorectal Cancer Trial (all trans Retinoic Acid, Atezolizumab, Bevacizumab)
Not yet recruiting
- Colorectal Cancer
- all trans Retinoic Acid
- +2 more
- (no location specified)
Aug 11, 2023
Patients With HHT. Follow up BABH
Completed
- Hemorrhagic Hereditary Telangiectasia
- HHT
- bevacizumab treatment
-
Angers, France
- +2 more
Sep 8, 2023
Colorectal Cancer, Peritoneal Metastases Trial in Eindhoven, Rotterdam (Irinotecan, FOLFOX regimen, Bevacizumab)
Recruiting
- Colorectal Cancer
- Peritoneal Metastases
- Irinotecan
- +2 more
-
Eindhoven, Netherlands
- +1 more
Aug 15, 2023
Colorectal Cancer Trial in Tai'an (Tas-102(Suyuan) combined with bevacizumab)
Not yet recruiting
- Colorectal Cancer
- Tas-102(Suyuan) combined with bevacizumab
-
Tai'an, Shandong, ChinaThe Second Affiliated Hospital of Shandong First Medical Univers
Oct 14, 2023
Glioblastoma Trial (Bevacizumab, PD-L1 t-haNK, N-803)
Not yet recruiting
- Glioblastoma
- Bevacizumab
- +2 more
- (no location specified)
Sep 25, 2023
Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus Trial (I-125 Seeds Brachytherapy in PVTT,
Not yet recruiting
- Hepatocellular Carcinoma
- +2 more
- I-125 Seeds Brachytherapy in PVTT
- +2 more
- (no location specified)
Aug 14, 2023
Bevacizumab Combined With PD-1 Monoclonal Antibody in
Not yet recruiting
- Colorectal Cancer
- Bevacizumab Combined With PD-1 Monoclonal Antibody
- (no location specified)
Nov 8, 2023
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With
Completed
- Metastatic Colorectal Adenocarcinoma
- Fruquintinib
- +3 more
-
Changsha, Hunan, ChinaHunan Cancer hospital
Sep 2, 2023
Metastatic Hepatocellular Carcinoma Trial in Houston (Atezolizumab, Bevacizumab, ADI-PEG 20)
Not yet recruiting
- Metastatic Hepatocellular Carcinoma
- Atezolizumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 24, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)
Recruiting
- Hepatocellular Carcinoma
- Candonilimab
- Bevacizumab
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
Feb 26, 2023
Hepatocellular Carcinoma (HCC) Trial (Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE))
Not yet recruiting
- Hepatocellular Carcinoma (HCC)
- Durvalumab
- +2 more
- (no location specified)
Sep 11, 2023
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Active, not recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +2 more
- Bevacizumab
- +2 more
-
Los Angeles, California
- +17 more
Jan 27, 2023
Breast Cancer With Brain Metastases Trial in Wuhan (pyrotinib+capecitabine+bevacizumab)
Recruiting
- Breast Cancer With Brain Metastases
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 22, 2023